Compartir
Información de la revista
Número
Vol. 28. Núm. 1.(enero - febrero 2023)
Editorials
Change of courier for Annals of Hepatology
Norberto Chávez-Tapia
Ann Hepatol. 2023;28:100893
Open access
Opinions
The treatment of diabetes in advanced liver disease: change of a paradigm
Maria Letizia Petroni, Lucia Brodosi, Giulio Marchesini
Ann Hepatol. 2023;28:100772
Open access
Concise reviews
Immunotolerance in liver transplantation: a primer for the clinician
Juanita Pérez-Escobar, Jose Victor Jimenez, Erika Faride Rodríguez-Aguilar, Maximiliano Servín-Rojas, Jesus Ruiz-Manriquez, Luisa Safar-Boueri, Eduardo Carrillo-Maravilla, Miquel Navasa, Ignacio García-Juárez
Ann Hepatol. 2023;28:100760
Open access
A thorny matter: Spur cell anemia
Ruchi Sharma, Carol J. Holman, Kyle E. Brown
Ann Hepatol. 2023;28:100771
Open access
Original articles
Choosing wisely recommendations regarding the top five list of procedures to avoid in the treatment of viral hepatitis: A position statement from the Brazilian Society of Hepatology endorsed by the Latin American Association for the Study of the liver
Cristiane A. Villela-Nogueira, Maria Lúcia Gomes Ferraz, Mário Guimarães Pessoa, Francisco José Dutra Souto, Letícia Cancella Nabuco, Henrique Sérgio Moraes Coelho, Ezequiel Ridruejo, Marcelo Silva, ... Members of the Brazilian Society of Hepatology
Ann Hepatol. 2023;28:100764
Open access
Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients
Haohui Deng, Yuzhen Mai, Huiyuan Liu, Jialong Guan
Ann Hepatol. 2023;28:100763
Open access
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
Mark Muthiah, Cheng Han Ng, Kai En Chan, Clarissa Elysia Fu, Wen Hui Lim, Darren Jun Hao Tan, Benjamin Nah, Gwyneth Kong, ... Mazen Noureddin
Ann Hepatol. 2023;28:100762
Open access
Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study
Samantha Thifani Alrutz Barcelos, Amanda Souza Silva-Sperb, Helena Abadie Moraes, Larisse Longo, Bruna Concheski de Moura, Matheus Truccolo Michalczuk, Carolina Uribe-Cruz, Carlos Thadeu Schmidt Cerski, ... Mário Reis Álvares-da-Silva
Ann Hepatol. 2023;28:100769
Open access
Liver steatosis and fibrosis markers’ association with cardiovascular and renal damage in Japanese adults: the TMM BirThree cohort study
Toshiya Machida, Taku Obara, Mami Ishikuro, Keiko Murakami, Fumihiko Ueno, Aoi Noda, Tomomi Onuma, Fumiko Matsuzaki, ... Nariyasu Mano
Ann Hepatol. 2023;28:100761
Open access
Magnitude and genotype of hepatitis delta virus among chronic hepatitis B carriers with a spectrum of liver diseases in Ethiopia
Yayehyirad Tassachew, Yeshambel Belyhun, Tamrat Abebe, Adane Mihret, Tezazu Teffera, Girma Ababi, Abate Shewaye, Hailemichael Desalegn, ... Melanie Maier
Ann Hepatol. 2023;28:100770
Open access
HOXB13 facilitates hepatocellular carcinoma progression by activating AKT/mTOR signaling pathway
Miao Li, Tingting Tan, Yu Geng, Yue Tao, Jie Pan, Jun Zhang, Qin Xu, Han Shen, ... Yuxin Chen
Ann Hepatol. 2023;28:100759
Open access
Testicular orphan receptor 4 induced hepatic stellate cells activation via the regulation of TGF-β receptor Ⅰ/Smad2/3 signaling pathway
Yadong Fu, Yuping Zhou, Yongping Mu, Ying Lv, Gaofeng Chen, Hua Zhang, Ping Liu, Jiamei Chen
Ann Hepatol. 2023;28:100775
Open access
New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD
Louise Torres, Alice Schuch, Larisse Longo, Bruna Bressan Valentini, Gabriela Schneider Galvão, Eduardo Luchese, Carlos Pinzon, Rodrigo Bartels, Mário Reis Álvares-da-Silva
Ann Hepatol. 2023;28:100774
Open access
Letters to the editor
Interpretive bias on research evidence: Striving to meet the trustworthiness criteria
Nahum Méndez-Sánchez, Eduardo Fassio, Shreya C. Pal
Ann Hepatol. 2023;28:100884
Open access
MAFLD vs. NAFLD not an emotional political process - rather Evidence-Based Medicine
Mark Muthiah, Arun J. Sanyal, Mazen Noureddin
Ann Hepatol. 2023;28:100883
Open access
Special issue on genomic medicine in obesity and chronic liver damage
Genomic medicine in hepatology: Towards personalized medicine in obesity and chronic liver disease
Sonia Roman, Omar Ramos-Lopez, Arturo Panduro
Ann Hepatol. 2023;28:100875
Open access
Activation of the NLRP3 inflammasome by CCl4 exacerbates hepatopathogenic diet-induced experimental NASH
Eduardo E. Vargas-Pozada, Erika Ramos-Tovar, Juan D. Rodriguez-Callejas, Irina Cardoso-Lezama, Silvia Galindo-Gómez, Karla Gil-Becerril, Verónica Rocío Vásquez-Garzón, Jaime Arellanes-Robledo, ... Pablo Muriel
Ann Hepatol. 2023;28:100780
Open access
Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: Systematic review and meta-analysis
Daniela Contreras, Alejandra González-Rocha, Patricia Clark, Simón Barquera, Edgar Denova-Gutiérrez
Ann Hepatol. 2023;28:100873
Open access
What do we know about nutrient-based strategies targeting molecular mechanisms associated with obesity-related fatty liver disease?
Ingrid Rivera-Iñiguez, Arturo Panduro, Sonia Roman, Karina González-Aldaco
Ann Hepatol. 2023;28:100874
Open access
Body mass index implications in intrahepatic cholestasis of pregnancy and placental histopathological alterations
Violeta Valdovinos-Bello, Carmen Selene García-Romero, Alicia Cervantes-Peredo, Elizabeth García-Gómez, Alejandra Martínez-Ibarra, Edgar Ricardo Vázquez-Martínez, Yolotzin Valdespino, Marco Cerbón
Ann Hepatol. 2023;28:100879
Open access
Publique en
Annals of Hepatology
Affiliated societies
